Drugs / JV-213
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1 | NCT05773040 | Apr 2023 → Dec 2028 expected | B-cell non-Hodgkin lymphoma | M.D. Anderson Cancer Center | Recruiting | No outcome recorded |
Evidence & citations 4 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | JV-213 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT05773040 ↗ |
| Modality | Cell therapy | “a type of autologous CAR T cell therapy” NCT05773040 ↗ |
| Route | Intravenous | “Given by (IV) vein” NCT05773040 ↗ |
| Target | CD79B | “CD79b-targeting” NCT05773040 ↗ |